- CLRB -2.57%
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Yahoo Finance · 2 weeks ago
Open | 3.1100 |
High | 3.1300 |
Low | 3.0150 |
Mkt Cap | 108.62M |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 3.1100 |
52 Wk. Low | 1.5600 |
52 Wk. High | 4.4500 |
Related stocks
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | - | - |
Net Income | -21.58M | - |
Diluted EPS | -1.28 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q4 2022 | -$1.00 | - |
Q3 2022 | -$1.21 | -$1.28 |
Q2 2022 | -$1.03 | -$1.22 |
S&P FuturesES=F | 5,371.00+7.00 (+0.13%) |
Dow FuturesYM=F | 39,024.00+69.00 (+0.18%) |
Nasdaq FuturesNQ=F | 19,098.50+38.25 (+0.20%) |
46.55+47.45% | |
5.79+12.43% | |
67.02+5.49% |